BioSeed Capital opens new office in London and becomes part of one of the most important centers worldwide in innovation and access to capital


Dec 2, 2016


The last November BioSeed Capital with headquarters in the Parc Científic of Barcelona established a new office in London to get access to UK’s market, one of the most powerful worldwide in healthcare startups, as well as in pharmaceutical firms.

Juan R. García, CEO of BioSeed Capital, explains how he sees this new business opportunity: “We work in a global sector where innovation requires an international presence for its commercialization. London is one of the most important centers worldwide in innovation and access to capital. We are sure that installing our headquarters there will help us to develop our international networking”.

The United Kingdom is a global center of excellence in Life Sciences and is the third most popular investment location in the world. Over £5 billion has been invested in the high-tech industries from the UK. Some data shows that nearly 750 companies of medical biotechnology are based in the UK with a combined turnover of £4.2 billion, representing an estimated 30% of European turnover in the sector. Furthermore, within these companies, 86% are engaged in research and development, resulting in innovation.

On another side, the pharmaceutical sector consists of around 600 companies with annual sales of around £15.6 billion, including big pharma’s headquarters of GlaxoSmithKline and AstraZeneca and other foreign companies with major presence in the UK including Pfizer, Novartis and Hoffmann-La Roche.

All this added to its university’s research excellence makes the United Kingdom in an essential spot in Europe to look for new markets.

Latest news

The first 2019 BioInternational Seminar is a success and gain interest between scientific profiles with vision in drug discovery

International experts shared their experience and knowledge in the pharmaceutical industry and the biotechnology sector over an evening with young scientific profiles developing their career in the drug discovery field

The Biotechnology Business Institute inaugurated the fifth edition of the master’s programs with the consolidation of its innovative educational model, Discover&Transfer

After the success of the first edition of the Discover&Transfer program, the new students of the Biotechnology Business Institute will develop new patents from the main research institutions of Barcelona.

The Biotechnology Business Institute signs a strategic collaboration agreement with IRB Barcelona, the Fundació Bosch i Gimpera and UPF, promoted by UPF Ventures, in a new educational model for drug discovery and technology transfer

The Biotechnology Business Institute (BBI) incorporates Discover & Transfer to the programs, where the students will be working with real drug candidates of these three institutions.

BIOSPAIN 2018 consolidates the congress as the 5th world biotechnology event

The ninth edition of the BIOSPAIN International Biotechnology Meeting, which ASEBIO organizes every two years, brought together more than 600 companies from 30 countries in the city of Seville.

Filter by category